RxDoctor Payments Data

Kelley Reynolds, MD

Family Medicine · McGregor, TXNPI 1528045846

Payments from drug & device makers

$495in general payments, 2019–2025

Across 32 payments — averaging $15.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$222
  • Merck$62
  • Lilly USA, LLC$53
  • AbbVie$43
  • Novo Nordisk$37
  • Exact Sciences$36
  • plus $42 from 3 others

What the payments were for

  • Food & beverage$495100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sunovion Pharmaceuticals Inc.18$222
Merck2$62
Lilly USA, LLC3$53
AbbVie(2 entities)2$43
Novo Nordisk2$37
Exact Sciences2$36
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$16
Pfizer1$16
Alpha Cognition USA, Inc.1$10

How this compares

$495 in reported general payments places this provider in the 50th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$5,367
Medicare patients
66
Services billed
360

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$95,852
EliquisApixaban30$33,197
JardianceEmpagliflozin21$29,726
XareltoRivaroxaban25$23,533
Breo ElliptaFluticasone/Vilanterol24$21,203
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$20,816
MounjaroTirzepatide12$14,822
Incruse ElliptaUmeclidinium Bromide12$9,634
Combivent RespimatIpratropium/Albuterol Sulfate13$5,984
Gabapentin175$4,645
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$4,621
Duloxetine Hcl65$2,065
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen69$2,036
Albuterol Sulfate HfaAlbuterol Sulfate67$1,896
Atorvastatin Calcium211$1,773

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$37$95,85274 claims
PfizerEliquis$16$33,19730 claims
Lilly USA, LLCMounjaro$53$14,82212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,760 family medicine providers in Texas.

Other family medicine in McGregor

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →